VEO Ophthalmics, LLC news

ADVANCEMENTS IN EYE CARE: FATHER-SON TEAM RESTORING SIGHT

At the height of the pandemic, across most medical specialties, doctors noted a sharp drop in care as patients curbed nonessential visits and procedures out of the fear that a medical appointment could lead to the coronavirus infection. But it wasn’t just dramatic specialties like cancer or heart care that saw collateral damage from COVID. Ophthalmology was hit the hardest of all. According to recent data

Louisiana’s first prosthetic iris implant was performed today at AVALA by Dr. Satya Reddy with Louisiana Cornea Specialists. The CUSTOMFLEX® ARTIFICIALIRIS Veo Ophthalmics implant was used to treat disabling glare as a result of infection over 15 years ago.

This surgery has never been performed in Louisiana and we are proud to offer some of the most innovative healthcare solut

VEO Ophthalmics, LLC announced today that, in honor of Rare Disease Day, it is collaborating with the Masket Foundation to raise awareness of aniridia and treatment options for aniridia. Aniridia is a serious ophthalmic rare disease in which a patient’s iris does not develop properly. VEO Ophthalmics is the U.S. distributor for the CUSTOMFLEX® ARTIFICIALIRIS, a custom-made artificial iris implant that addresses both symptomatic and cosmetic aspects of iris defects. VEO Ophthalmics a

VEO Ophthalmics, LLC, today announced that the CUSTOMFLEX® ARTIFICIALIRIS has been approved by the Center for Medicare and Medicaid Services (CMS) for transitional pass‐through payment status, effective January 1, 2020. The HCPCS code for the CUSTOMFLEX® ARTIFICIALIRIS that is associated with pass‐through payment is: C1839 Iris prosthesis.

The approval by CMS for transitional pass‐through payment was under the new alternative pathway for Breakthrough devic

VEO Ophthalmics, LLC, today announced the launch of the CUSTOMFLEX ^® ARTIFICIALIRIS, the first iris prosthesis available in the United States. The surgically implanted device received FDA approval on May 30, 2018 for use in children and adults for the treatment of iris defects resulting from congenital aniridia, acquired defects or other conditions associated with a completely or partially missing or damaged iris.

VEO has entered into an exclusive agreeme